We have previously reported that immunization of the severe combined immunodeficiency (SCID) mice reconstituted with human peripheral blood mononuclear cells (PBMC) (hu-PBL-SCID mice) with inactivated human immunodeficiency virus type-1 (HIV-1)-pulsed-autologous dendritic cells (HIV-DC) elicits HIV-1-reactive CD4 þ T cells that produce an as yet to be defined novel soluble factor in vitro with anti-viral properties against CCR5 tropic (R5) HIV-1 infection. These findings led us to perform studies designed to identify the lineage of the cell that synthesizes such a factor in vivo and define the epitopes of HIV-1 protein that have specificity for the induction of such anti-viral factor. Results of our studies show that this property is a function of CD4 þ but not CD8 þ T cells. Human CD4 þ T cells were thus recovered from the HIV-DC-immunized hu-PBL-SCID mice and were re-stimulated in vitro by co-culture for 2 days with autologous adherent PBMC as antigen presenting cells, APC previously pulsed with inactivated HIV in IL-2-containing medium to expand HIV-1-reactive CD4 þ T cells. Aliquots of these re-stimulated CD4 þ T cells were then co-cultured with similar APC's that were previously pulsed with 10 mg/ml of a panel of HIV peptides for an additional 2 days, and their culture supernatants were examined for the production of both the R5 HIV-1 suppression factor and IFN-g. The data presented herein show that the HIV-1 primed CD4 þ T cells produced the R5 suppression factor in response to a wide variety of HIV-1 gag, env, pol, nef or vif peptides, depending on the donor of the CD4 þ T cells. Simultaneous production of human interferon (IFN)-g was observed in some cases. These results indicate that human CD4 þ T cells in PBMC of HIV-1 naive donors have a wide variety of HIV-1 epitope-specific CD4 þ T cell precursors that are capable of producing the R5 HIV-1 suppression factor upon DC-based vaccination with whole inactivated HIV-1.
Introduction
Virus specific CD4 þ helper T (Th) cell responses have been shown to play an essential role in the maintenance of effective immune responses in a variety of animal models [3, 12, 20, 32, 34] . Human immunodeficiency virus type 1 (HIV-1) infection is associated with a progressive loss of total CD4
þ Th cells by both direct and indirect mechanisms [21, 25, 27, 28, 30] . In particular, memory CD4
þ Th cells become more susceptible to the cytopathic effects of HIV-1 than naive CD4
þ Th cells after activation [8] . Several lines of evidence strongly suggest that HIV-1-specific CD4 þ Th cells are critical for control of HIV-1 in part by maintaining HIV-1-specific CD8 þ cytotoxic T lymphocyte (CTL) responses [13, 17, 22, 23, 26, 28] . Highlighting the complexity of HIV-1 infection was the finding that HIV-1-specific CD4
þ Th cells were in fact preferentially infected by HIV-1 in vivo [9] . It was reasoned that such mechanisms may indeed contribute to an impairment in the control of not only HIV-1 but also opportunistic infections. While such CD4 þ T cell depletion continues to occur with variable kinetics in HIV-1 infected patients, a significant frequency of HIV-1-specific CD4
þ Th cells are detectable in most of these individuals with a higher frequency in long-term nonprogressors (LTNP) than in subjects during progressive disease [4, 28, 37, 38] . In addition to the traditional function of CD4 þ T cells in facilitating the generation of HIV-1 specific CD8 þ T cells and the synthesis of antibodies, CD4
þ Th cells from HIV-1 infected patients have also been shown to exert anti-viral effects not only by direct lysis of HIV-1 infected target cells by HIV-1 gag specific CD4 þ T cells [18] but also by the secretion of a variety of HIV-1 suppression factors [1, 15, 31, 41] . These findings together suggest that CD4 þ T cells from HIV-1 infected and/or immunized individuals have acquired a series of unique anti-viral activity which may contribute to the control of viremia and the detailed studies of the mechanisms by which such activity is acquired and induced thus appears warranted. We have previously reported that SCID mice engrafted with HIV-1-naive human PBMC together with autologous DC pulsed with inactivated whole HIV-1 virion became subsequently completely resistant to R5 HIV-1 challenge in vivo. The resistance to infection was specific since it was only seen in the hu-PBL-SCID mice immunized with inactivated R5 or X4 HIV-1 virions, but not OVA or KLH. Studies of the mechanisms by which these mice were protected led to the discovery of a novel soluble anti-viral factor produced in the serum of these HIV-DC immune mice. While this factor synthesized by human CD4 þ T cells from the hu-PBL-SCID HIV-1 immunized mice was unable to neutralize HIV-1 in vitro, it was capable of inhibiting R5, but not X4 HIV-1 infection of primary macrophages and activated PBMC which was not secondary to the down regulation of either CCR5 or CD4 and appeared to act prior to viral integration. Of interest was also the finding that the factor was not effective in controlling R5 HIV-1 infection of CCR5-expressing CD4 þ T cell lines. Since the generation of the suppressor factor appeared to be specifically induced by HIV-1 immunization of the hu-PBL-SCID mice, it was reasoned that the delineation of the epitopes of the HIV-1 encoded proteins that induce the generation of such factors would be appropriate and informative. Results of such studies are the basis of this report.
Materials and methods

Mice
SCID mice lacking functional T, B and natural killer cells (NK), BALB/c-rag2
2/2 gc 2/2 [24] were used in the present study. The mice were kept in a SPF and BSL-3 animal facilities of the Laboratory Animal Center, University of the Ryukyus. The protocols for the care and use of hu-PBL-SCID mice have been approved by the committee on animal research of the University of the Ryukyus.
Reagents
RPMI 1640 medium (SIGMA, St Louis, MO) supplemented with 5% fetal calf serum (FCS), 100 U/ml of penicillin and 100 mg/ml of streptomycin (hereinafter called RPMI medium), serum free medium (AIM-V) and Iscove's medium (Lifetechnology, NY) supplemented with 10% FCS with the antibiotics (hereinafter called AIM-V medium and Iscove's medium) were utilized as sources of media. Soluble recombinant human IL-4 and GM-CSF were produced in 293 T cells transfected with pCMhIL4 and pCMhGM (RIKEN Gene Bank, Ibaraki, Japan), respectively, by the calcium phosphate method [33] and purified. Concentrations of human IL-4 and GM-CSF were determined using commercial ELISA kits (BioSource, Camarillo, CA). Human recombinant IL-2 was kindly supplied by NIH AIDS Research and Reference Program.
Blocking monoclonal antibodies (mAb) against human MIP-1a, human MIP-1b and human RANTES were purchased from R&D systems (Rockville, MD). To maintain their blocking activity, these antibodies in a lyophilized form were reconstituted in accordance with the manufacturer's instructions, and aliquots were kept at 2 808C until use. Heparin -Sepharose (Pharmacia, Sweden) was used to absorb b-chemokines as described previously in Ref. [39] .
HIV-1 peptides were obtained from the NIH AIDS Research and Reference Program, including the complete sets of the HIV-1 HXB2 gag peptides (Cat#5107 and Cat#3992), HIV-1 MN env peptides (Cat#6451), HIV-1 HXB2R pol peptides (Cat#4358), HIV-1 clade B nef peptides (Cat#5189), HIV-1 consensus B vif peptides (Cat#6445), HIV-1 consensus B rev peptides (Cat#6445), HIV-1 BRV nef peptides (Cat#6441) and HIV-1 consensus vpu peptides (Cat#6444). Each peptide was dissolved in DMSO at a concentration of 10 mg/ml, and then diluted in RPMI medium at 10 mg/ml prior to use.
Viruses
HIV-1 JR-CSF [16] and HIV-1 NL4-3 [2] viral stocks were each produced in the 293T cells by transfection with the appropriate HIV-1 infectious plasmid DNA utilizing the calcium phosphate method [33] . HIV-1 IIIB was harvested from Molt-4/IIIB cell cultures. The 50% tissue culture infectious dose (TCID 50 ) was determined by an endpoint infectious assay using PBMC stimulated with anti-CD3/anti-CD28-mAb conjugated DynaBeads (Dynal, Oslo, Norway). HIV-1 preparations were inactivated with Aldrithiol-2 (AT-2), as originally described by Rossio et al. [29] .
Generation of HIV-1 pulsed mature DC's from monocytes Fresh PBMC at 5 £ 10 6 cells/ml in RPMI medium were dispensed into individual wells of 12-well plates (1 ml/well), which had been precoated with autologous plasma for 30 min at 378C. The PBMC cultures were allowed to incubate at 378C for 1 h. The non-adherent cells were removed by gentle washing with serum-free RPMI 1640 medium and the remaining adherent cells were cultured in Iscove's medium (2 ml/well) containing human GM-CSF (500 ng/ml) and IL-4 (200 ng/ml) for 5 days. The resulting immature DC cultures were depleted of contaminating lymphocytes by using the monocytenegative isolation kit (Dynal, Oslo, Norway), and the enriched population of DC's were further cultured at 2 £ 10 6 /ml in human IFN-b (1000 U/ml; Toray, Tokyo, Japan) in the presence of AT-2 inactivated whole HIV-1 (containing 50 ng/ml p24) for 2 days to obtain mature DC pulsed with HIV-1, as described previously in ref. [39] .
Transplantation and immunization
HIV-1-pulsed mature DC (5 £ 10 5 cells) mixed with autologous fresh PBMC (3 £ 10 6 cells), or those depletes of CD8 þ T cells, or CD4 þ T cells by a magnetic isolation method (Dynal, Oslo, Norway) in a final volume of 100 ml in RPMI medium were injected into the spleen of SCID mice. Five days later, the same number of DC pulsed with the same dose of HIV-1 antigen were inoculated into the peritoneal cavity. Five days later, the mice were sacrificed and human lymphocytes were recovered from the spleen and the peritoneal cavity by lavage.
In vitro re-stimulation of CD4 1 
T cells
The recovered human lymphocytes from the HIV-DC immune mice were depleted of human CD8 þ cells by the magnetic beads-negative selection method (Dynal). These enriched population of human CD4 þ T cells (2 £ 10 6 cells) were co-cultured with freshly obtained 2 £ 10 5 autologous mitomycin-C treated adherent PBMC as antigen presenting cells (APC), in the presence of AT-2 inactivated HIV-1 containing 50 ng p24 in a volume of 1 ml RPMI 1640 medium supplemented with 20 U/ml human IL-2 in individual wells of a 24-well plate (BD Pharmingen, San Diego, CA) at 378C. Two days later, these CD4 þ T cells were assayed for HIV-1 peptide specific responses as follows. An initial screening was performed utilizing pools of 10 sequential overlapping peptides and once a pool of peptides was shown to lead to the synthesis of the HIV-1 suppression factor, a second screening was performed to identify the individual peptide. Thus, enriched population of 2 £ 10 4 autologous APC were first dispensed in a volume of 50 ml into individual wells of a 96-well microtiter plate and triplicate wells incubated with 50 ml of media containing the various individual pools of 10 HIV-1 peptides for the primary screen (each at 10 mg/ml) or an individual HIV-1 peptide for the secondary screen (10 mg/m) for 1 h at 378C. A total of 2 £ 10 5 HIV-1 primed and in vitro re-stimulated CD4 þ T cells were then added to these cultures in a volume of 100 ml of media and the co-cultures incubated at 378C in a 5% CO 2 humidified atmosphere. Two days later, the culture supernatants were harvested and aliquots assayed for HIV-1 inhibition activity and levels of IFN-g.
HIV-1 inhibition and IFN-g assays
As previously reported [39] , PBMC were activated with anti-CD3/28 antibody-coated magnetic beads (Dynal) at cell to bead ratio of 1:1 in 20 U/ml IL-2 containing RPMI medium in vitro for 3 days. These activated PBMC's (5 £ 10 5 cells/well) were preincubated at 378C for 1 h with either various dilution of serum from the HIV-DC immune mice or culture supernatants obtained from the CD4 þ T cells that were stimulated with various HIV-1 peptides as described above. Five hundred TCID 50 of HIV-1 JR-CSF or HIV-1 NL4-3 was then added to these cultures for an additional 4 h. The microtiter plate was centrifuged and the supernatant fluid removed. The procedure repeated three times and the cultures then were incubated in 0.2 ml of 20 U/ml IL-2-containing RPMI medium for 5 days. The levels of HIV-1 p24 produced in the culture supernatants were determined by a commercial ELISA kit (Zepto Metrix, Buffalo, NY). Levels of human IFN-g in the stimulated culture supernatants were assayed utilizing a commercial ELISA kit (R&D Systems Inc., Minneapolis, MN).
HLA typing
Donor PBMC were HLA typed by a DNA typing method.
Results
In order to identify the lineage of cells that was the major producer of the R5 HIV-1 suppression factor in vivo, SCID mice were engrafted with unfractionated PBMC or PBMC depleted of either CD4 þ or CD8 þ cells, together with HIV-DC. Various dilutions of the immune sera from these mice were then examined for the R5 HIV-1 suppression activity in vitro. As seen in Figure 1 , as little as 5% of the sera from the mice engrafted with either unfractionated PBMC or CD8-depleted PBMC significantly ( p , 0.05) inhibited R5 HIV-1 infection. In contrast, up to 20% of the sera from the CD4-depleted PBMC-engrafted mice did not show any detectable R5 HIV-1 suppressive activity. Similar assays conducted using X4 HIV-1 failed to show any inhibition denoting that the inhibition was selective for R5 HIV-1 (data not shown). In these engrafted mice, the levels of human CD4 þ and CD8 þ T cells existed at similar levels as in the mice engrafted with unfractionated PBMC (data not shown). These data indicate that CD8 þ T cells are not required for the production of the R5 HIV-1 suppression factor in vivo, and that the HIV-immune human CD4
þ T cell population is the major source for the R5 HIV-1 suppression factor in vivo.
In efforts to map the epitopes of HIV-1 antigens that lead to the activation of CD4 þ T cells and the subsequent release of the HIV-1 suppression factor, a large panel of 15 -20 mer peptides spanning a wide range of HIV-1 proteins were screened using a re-stimulation assay as described in the methods section. In order to enrich for HIV-1 antigenresponding CD4 þ T cells in vitro, CD8 þ T celldepleted lymphocytes obtained from three groups of HIV-DC immune hu-PBL-SCID mice, which had been engrafted with PBMC's from different individuals, were first stimulated with inactivated whole HIV-1 in the presence of autologous APC in vitro. These HIV-1-primed enriched CD4 þ T cells were then re-stimulated by co-culture in the presence of a pool of 10 HIV-1 peptides with fresh APC for primary screening. After 2 days, culture supernatants were harvested and examined for the R5 HIV-1 suppression factor at a final dilution of 50%. Supernatant fluids giving values of . 50% reduction compared to controls (incubated with media alone) in p24 antigen synthesized in the R5 HIV-1 infected cells were considered positive and a secondary screen performed to identify the individual HIV peptide inducing such HIV-1 suppression factor activity. In order to make sure that the R5 HIV-1 suppression was not mediated by CCR5-binding b-chemokines, the culture supernatants to be tested were individually pre-absorbed by incubation with Heparin -Sepharose followed by incubation with a pool of blocking mAbs against human RANTES, MIP-1a and MIP-1b each a concentration of 10 mg/ml. Figure 2a -c shows representative data from a number of independent experiments conducted on cells from the three donors, respectively. These data suggest that the ability of HIV-1 peptides to induce the HIV-1 suppressor factor resides in multiple HIV-1 peptides from a number of HIV-1 proteins. As expected, there were variations noted in the HIV-1 proteins and peptides that induce the HIV-1 suppression factor in the three individual donors. The peptides recognized by donor 1 CD4 þ T cells consisted of peptides from HIV-1 pol, gag and env antigens, while those recognized by donor 2 were of gag, env, vif and rev antigens, and those recognized by donor 3 were of gag, env, vif and rev antigens. None of the supernatant fluids examined showed detectable X4 HIV-1 suppression activity in the assay employed (data not shown). There was specificity in the assay since the R5 HIV-1 suppression factor was not detected either in the culture supernatants from APC cultured with or without HIV-1 peptides alone or supernatant fluids from immune CD4 þ T cells cultured in the absence of APC or peptides (data not shown). The individual variations in the response to peptides may be due to HLA restriction of responding antigenic peptides, as the three donors were of different HLA class II type (Table I) . It is interesting to note that the production of the R5 HIV-1 suppression factor by the bulk CD4 þ T cells was 4 APC in a volume of 200 ml in individual wells of a 96-well plate. After 2 days, the culture supernatants were harvested and their activity of R5 HIV-1 inhibition and the levels of human IFN-g were determined as described in the materials and methods. Percent inhibition of HIV-1 production was calculated using values obtained from HIV-1 infected PBMC that were pre-treated with the medium alone. Representative data from three independent experiments for donor 1 (a), donor 2 (b), and donor 3 (c) were shown.
accompanied by the production of human IFN-g but not in all the cases.
Discussion
Our laboratory has previously documented the synthesis of a soluble factor by CD4 þ T cells isolated from SCID mice previously engrafted with a mixture of human PBMC's and HIV-1-pulsed autologous DC's which suppressed infection of R5 HIV-1 in vitro [39] . In the present study we have identified the CD4 þ T cell lineage as a requirement for the synthesis of this factor in vivo. In addition, we have attempted to identify the HIV-1 epitopes that are recognized by CD4 þ T cells that lead to the synthesis of this factor. There are a number of issues that need to be addressed in light of these findings. Thus, first of all, we submit that the anti-viral factor is distinct from the other anti-viral factors that have been previously identified. The fact that the suppressor activity was not neutralized by the addition of antibodies against the chemokines RANTES, MIP-1a and MIP-1b suggest that such suppression is not likely due to the synthesis of these chemokines which are known inhibitors of viral infection [7, 36] . The factor described herein is also distinct from the cellular anti-viral factor (CAF) identified by the laboratory of Dr Jay Levy [19] since it is synthesized by CD4 þ T cells but not CD8 þ T cells and whereas Dr Levy's CAF is effective against all HIV-1, HIV-2 and select retroviruses. The factor reported herein appears to be specific for R5 but not X4 tropic HIV-1. In addition, it is not likely to be either lymphotactin [35] , a-defensins [40] , the heparin binding protein termed anti-thrombin III [10] , the natural killer enhancing factors A and B [11] , and some additional factors (reviewed by Levy et al. [5] ) since all of these have been shown to be synthesized primarily by CD8 þ but not CD4 þ T cells. There has been an anti-viral factor that is synthesized following the interaction of CD4 þ T cells with APC's [6] . However, this factor is functionally distinct from our factor because the factor inhibits HIV-1 production at post-integration stage, and our factor inhibits R5 HIV-1 infection prior to integration [39] . It is clear though that there are a plethora of such anti-viral factors that have been and continue to be described. The biologic reasons for such a multitude of anti-viral factors is difficult to imagine except to state that these are likely due to redundancies that nature has bestowed on the vertebrate species to protest itself from such viral infections.
The second issue concerns the multiple epitopes of HIV-1 that induce the generation of this factor by CD4 þ T cells. These epitopes interestingly were not restricted to a single HIV-1 protein and included both viral structural and accessory proteins. The obvious individual variations in responding antigenic peptides suggests that this maybe due to HLA-restriction of peptide recognition by the immune CD4 þ T cells, although additional studies are necessary to confirm this issue. Furthermore, the present study suggests that the CD4 factor-producing HIV-1-immune CD4 þ T cells are heterogeneous Th clones. Since the peptides tested in this study were overlapping 15 -20 mers, an additional study is required to more precisely define the specific HIV-1 epitope that has specificity for the CD4 þ T cells. It is also unclear whether the suppressor factor synthesized by CD4 þ T cells in response to distinct HIV peptides is identical or distinct. Biochemical identification of the factor(s) is needed to address this issue and such studies are in progress.
The next issue concerns the synthesis of IFN-g by some but not all the CD4 þ T cell in the assays reported herein. Since the cultures performed consisted of a mixture of CD4 þ T cells, it is not clear whether the synthesis of the anti-viral factor and IFN-g was the result of a single clonal population of multiple clones of CD4 þ T cells. Clonal analysis needs to be performed to address this issue.
It is important to note that the HIV-1 gag p17 antigen peptide (LERFAVNPGLLETSE) recognized by the HIV-DC immune CD4 þ T cells from two out of the three donors shares amino acid sequence with another gag p17 peptide (ERFAVNPGLLETSEGCR) that is widely recognized by IFN-g-producible CD4 þ T cells from at least 25% HIV-1-infected individuals [14] . These results strongly support the use of DCbased vaccination of hu-PBL-SCID mice with whole inactivated HIV-1 virion to stimulate and expand HIV-1-specific CD4 þ T cells in efforts to study the effectiveness of these cells for anti-viral control. More importantly, it should be noted that the CD4 factor producing CD4 þ T cells generated in the hu-PBL-SCID mice recognize multiple HIV-1 proteins similar the studies that have reported for HIV-1-specific IFNg producing CD4 þ T cells in HIV-1 infected individuals [39] . Although, the existence and clinical role of the CD4 factor in HIV-1-infected individuals remains unknown, the data reported herein suggest that HIV-1 vaccines containing multiple HIV-1 epitopes or proteins, rather than those with single HIV-1 protein or epitope, will be likely to be more effective in expanding a large number of multiple HIV-1-reactive CD4 þ T cells that are capable of producing the CD4 factor and other helper and HIV-1-suppresing cytokines. As far as we know up to present, there have been no reports on cytokines that are identical to the CD4 antiviral factor described herein. Attempts to identify the biochemical nature of this novel anti-viral factor have been hampered by both our inability to prepare sufficiently large quantities that are required for both biochemical identification and detailed characterization of this molecule coupled with the labile nature of the molecule. Fortunately, in our recent attempts, we have succeeded in immortalizing CD4 factor-producing CD4 þ T cells by HTLV-I-mediated transformation (Yoshida et al. unpublished) . These cells will be helpful for the identification of not only the factor itself, but also its putative receptor.
